全球双特异性抗体药物研发格局分析*

过去十年,全球双特异性抗体研发取得了突破性进展,4款产品获批上市,多个产品进入临床及临床前研究。双抗具有区别于单抗的独特生物学机制,有望成为针对癌症、自身免疫和传染病的下一代生物疗法,但双抗药物的开发更具复杂性,有着更高的技术壁垒。通过对全球双抗总体研发进展、企业研发格局、产品研发进展等角度分析,以期为相关企业的双抗研发方向选择及地区产业决策提供参考。

Analysis of the Current Status of Global Bispecific Antibody Development

The past decade has seen breakthrough progress in bispecific antibody development worldwide, with four products approved for marketing and multiple products entering clinical and preclinical studies. With a unique biological mechanism that distinguishes them from mAbs, dual antibodies hold promise as the next generation of biologic therapies against cancer, autoimmune, and infectious diseases, but the development of dual antibodies is more complex and has higher technical barriers. In this paper, we analyze the global progress in the overall development of dual antibody, the landscape of corporate R & D, and the progress of product R & D in the future, in order to provide references for the choice of direction of dual antibody R & D for related firms and the regional industrial decision.